Sort
85,873 grants matching “alzheimers”
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease
$13,634,548Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2021 · AG
Johns Hopkins Institute for Clinical and Translational Research
$13,495,542Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2020 · TR
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)
$13,319,036Karen P Alexander · Duke University · U19 · FY2024 · AG
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)
$13,212,214Charles Decarli · University Of California At Davis · U19 · FY2021 · NS
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$13,195,325Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2024 · AG
Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months
$13,127,747Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2024 · AG
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$13,002,977Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2021 · AG
Gross Hall Animal Resource Center
$12,970,423Pramod P Khargonekar · University Of California-Irvine · C06 · FY2010 · RR
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$12,764,241Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2019 · AG
Core D: Medicinal Chemistry Core
$12,760,250Timothy M Willson · Univ Of North Carolina Chapel Hill · U19 · FY2022 · AI
California National Primate Research Center
$12,683,326Prasant Mohapatra · University Of California At Davis · P51 · FY2021 · OD
Consortium for Alzheimers Sequence Analysis (CASA)
$12,638,607Gerard David Schellenberg · University Of Pennsylvania · UF1 · FY2014 · AG
California National Primate Research Center
$12,623,145Jeffery C Gibeling · University Of California At Davis · P51 · FY2022 · OD
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$12,618,678Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2023 · AG
A Randomized, Double-Blind, Placebo-Controlled Study of LHP588 in Subjects with P. gingivalis-Positive Alzheimer's Disease
$12,591,952Michael J. Detke · Lighthouse Pharmaceuticals, Inc. · R01 · FY2025 · AG
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$12,500,000Susan Abushakra · Alzheon, Inc. · R01 · FY2021 · AG
Alzheimer's Disease Cooperative Study
$12,480,297Paul S. Aisen · University Of California, San Diego · U19 · FY2014 · AG
Precision Aging Network: Closing the Gap Between Cognitive Healthspan andHuman Lifespan
$12,472,457Carol A. Barnes · University Of Arizona · U19 · FY2021 · AG
Clinical Operations and Procedures Core
$12,461,651Marinella Temprosa · Columbia University Health Sciences · U19 · FY2023 · AG
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
$12,228,673Bradley F Boeve · Mayo Clinic Rochester · U19 · FY2020 · AG
Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old
$12,173,143Rachel A Whitmer · University Of California At Davis · RF1 · FY2017 · AG
ALZHEIMER'S DISEASE COOPERATIVE STUDY
$12,123,984University Of California San Diego · U01 · FY2003 · AG
Precision Aging Network: Closing the Gap Between Cognitive Healthspan andHuman Lifespan
$12,089,034Carol A. Barnes · University Of Arizona · U19 · FY2024 · AG
Clinical Operations and Procedures Core
$12,055,505Marinella Temprosa · Columbia University Health Sciences · U19 · FY2022 · AG
ALZHEIMER'S DISEASE COOPERATIVE STUDY
$12,004,726University Of California San Diego · U01 · FY2004 · AG